Prior to joining the firm, Eric was an associate at an intellectual property, antitrust and corporate law boutique primarily handling intellectual property counseling matters, including intellectual property litigation, for pharmaceutical, medical device and technology companies.
Eric is an associate in the Intellectual Property Transactions Group.
Eric is an associate in the Intellectual Property Transactions Group.
Expertise
Experience
Representative matters
Intercontinental Exchange, Inc. in its pending acquisition of Black Knight, Inc., a deal valued at approximately $13 billion.
Anglo American in its ongoing combination of First Mode with Anglo American's nuGen Zero Emissions Haulage Solution.
SAP SE in its pending sale of SAP Litmos to Francisco Partners.
A prominent media and broadcasting company in connection with partnerships for the creation, distribution and exploitation of digital content.
A sovereign wealth fund in connection with partnerships for the rebranding and operation of luxury hotel properties.
A precision medicine company in connection with a data collaboration leveraging molecular profiling data with clinical documentation.
Published Work
- E. Dunbar and C. Landmon, IP and Collaboration, 41 Pharmaceutical Executive, 21-22 (Mar. 11, 2021)
- E. Dunbar and C. Landmon, Insights on the MODERN Labeling Act, Axinn FDA Update (Nov. 20, 2020
- E. Dunbar and J. Harris, Prosecution Counsel Beware: Statutory Bars and Inequitable Conduct, Axinn IP Update Mar. 19, 2020)
- E. Dunbar, et al., 3 Strategies to Manage Case Scope in ANDA Patent Litigation, Law360 (Dec. 10, 2019)
Qualifications
Admissions
Courts
United States District Court for the Southern District of New York
United States District Court for the Eastern District of New York
Academic
Boston University School of Law J.D.
University of Chicago B.A., Biological Science, Public Policy